2. Academic Validation
  3. C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma

C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma

  • Cancers (Basel). 2021 Jan 13;13(2):270. doi: 10.3390/cancers13020270.
Raphael Wilhelm 1,  Timon Eckes 1,  Gergely Imre 1,  Stefan Kippenberger 2,  Markus Meissner 2,  Dominique Thomas 3,  Sandra Trautmann 3,  Jean-Philippe Merlio 4,  Edith Chevret 4,  Roland Kaufmann 2,  Josef Pfeilschifter 1,  Alexander Koch 1,  Manuel Jäger 2 5
Affiliations

Affiliations

  • 1 Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany.
  • 2 Department of Dermatology, Venerology and Allergology, Goethe University Hospital, 60590 Frankfurt am Main, Germany.
  • 3 Department of Clinical Pharmacology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany.
  • 4 Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology, Bordeaux University, 33076 Bordeaux, France.
  • 5 Hautklinik, Städtisches Klinikum Karlsruhe, Akademisches Lehrkrankenhaus der Universität Freiburg, 76133 Karlsruhe, Germany.
PMID: 33450826 DOI: 10.3390/cancers13020270
Abstract

Cutaneous T cell lymphomas (CTCLs) represent a heterogeneous group of T cell lymphomas that primarily affect the skin. The most frequent forms of CTCL are mycosis fungoides and Sézary syndrome. Both are characterized by frequent recurrence, developing chronic conditions and high mortality with a lack of a curative treatment. In this study, we evaluated the effect of short-chain, cell-permeable C6 Ceramide (C6Cer) on CTCL cell lines and keratinocytes. C6Cer significantly reduced cell viability of CTCL cell lines and induced cell death via Apoptosis and necrosis. In contrast, primary human keratinocytes and HaCaT keratinocytes were less affected by C6Cer. Both keratinocyte cell lines showed higher expressions of ceramide catabolizing Enzymes and HaCaT keratinocytes were able to metabolize C6Cer faster and more efficiently than CTCL cell lines, which might explain the observed protective effects. Along with Other existing skin-directed therapies, C6Cer could be a novel well-tolerated drug for the topical treatment of CTCL.

Keywords

C6 ceramide; cutaneous T cell lymphoma; short-chain ceramide; skin.

Figures
Products